PURPOSE: To assess treatment efficacy using spectral-domain (SD) optical coherence tomography (OCT) measurements of papilledema in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), which evaluated the effects of acetazolamide and weight management and of placebo and weight management in eyes with mild visual loss. DESIGN: Randomized double-masked control clinical trial of acetazolamide plus weight management compared with placebo plus weight management in subjects with mild visual field loss and previously untreated idiopathic intracranial hypertension (IIH). PARTICIPANTS: Eighty-nine (43 acetazolamide treated, 46 placebo treated) of 165 subjects meeting IIHTT entry criteria. METHODS: Subjects underwent perimetry, papilledema grading (Frisén method), high- and low-contrast visual acuity, and SD OCT imaging at study entry and 3 and 6 months. Study eye results (worse perimetric mean deviation [PMD]) were used for most analyses. MAIN OUTCOME MEASURES: Retinal nerve fiber layer (RNFL) thickness, total retinal thickness (TRT), optic nerve (ONH) volume, and retinal ganglion cell layer (RGCL) measurements derived using 3-dimensional segmentation. RESULTS:Study entry OCT values were similar in both treatment groups. At 6 months, the acetazolamide group had greater reduction than the placebo group for RNFL thickness (175 μm vs. 89 μm; P = 0.001), TRT (220 μm vs. 113 μm; P = 0.001), and ONH volume (4.9 mm(3) vs. 2.1 mm(3); P = 0.001). The RNFL thickness (P = 0.01), TRT (P = 0.003), and ONH volume (P = 0.002) measurements also showed smaller increases in subjects who lost 6% or more of study entry weight. The acetazolamide (3.6 μm) and placebo (2.1 μm) groups showed minor RGCL thinning (P = 0.06). The RNFL thickness, TRT, and ONH volume measurements showed moderate correlations (r = 0.48-0.59; P ≤ 0.0001) with Frisén grade. The 14 eyes with RGCL thickness less than the fifth percentile of controls had worse PMD (P = 0.001) than study eyes with RGCL in the fifth percentile or more. CONCLUSIONS: In IIH, acetazolamide and weight loss effectively improve RNFL thickness, TRT, and ONH volume swelling measurements resulting from papilledema. In contrast to the strong correlation at baseline, OCT measures at 6 months show only moderate correlations with papilledema grade.
RCT Entities:
PURPOSE: To assess treatment efficacy using spectral-domain (SD) optical coherence tomography (OCT) measurements of papilledema in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), which evaluated the effects of acetazolamide and weight management and of placebo and weight management in eyes with mild visual loss. DESIGN: Randomized double-masked control clinical trial of acetazolamide plus weight management compared with placebo plus weight management in subjects with mild visual field loss and previously untreated idiopathic intracranial hypertension (IIH). PARTICIPANTS: Eighty-nine (43 acetazolamide treated, 46 placebo treated) of 165 subjects meeting IIHTT entry criteria. METHODS: Subjects underwent perimetry, papilledema grading (Frisén method), high- and low-contrast visual acuity, and SD OCT imaging at study entry and 3 and 6 months. Study eye results (worse perimetric mean deviation [PMD]) were used for most analyses. MAIN OUTCOME MEASURES: Retinal nerve fiber layer (RNFL) thickness, total retinal thickness (TRT), optic nerve (ONH) volume, and retinal ganglion cell layer (RGCL) measurements derived using 3-dimensional segmentation. RESULTS: Study entry OCT values were similar in both treatment groups. At 6 months, the acetazolamide group had greater reduction than the placebo group for RNFL thickness (175 μm vs. 89 μm; P = 0.001), TRT (220 μm vs. 113 μm; P = 0.001), and ONH volume (4.9 mm(3) vs. 2.1 mm(3); P = 0.001). The RNFL thickness (P = 0.01), TRT (P = 0.003), and ONH volume (P = 0.002) measurements also showed smaller increases in subjects who lost 6% or more of study entry weight. The acetazolamide (3.6 μm) and placebo (2.1 μm) groups showed minor RGCL thinning (P = 0.06). The RNFL thickness, TRT, and ONH volume measurements showed moderate correlations (r = 0.48-0.59; P ≤ 0.0001) with Frisén grade. The 14 eyes with RGCL thickness less than the fifth percentile of controls had worse PMD (P = 0.001) than study eyes with RGCL in the fifth percentile or more. CONCLUSIONS: In IIH, acetazolamide and weight loss effectively improve RNFL thickness, TRT, and ONH volume swelling measurements resulting from papilledema. In contrast to the strong correlation at baseline, OCT measures at 6 months show only moderate correlations with papilledema grade.
Authors: Vardanian Vartin C; A M Nguyen; T Balmitgere; M Bernard; C Tilikete; A Vighetto Journal: Br J Ophthalmol Date: 2011-06-07 Impact factor: 4.638
Authors: Michael Wall; Michael P McDermott; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Mark J Kupersmith Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: William S Fischer; Michael Wall; Michael P McDermott; Mark J Kupersmith; Steven E Feldon Journal: Invest Ophthalmol Vis Sci Date: 2015-05 Impact factor: 4.799
Authors: Alexandra J Sinclair; Michael A Burdon; Peter G Nightingale; Timothy D Matthews; Andrew Jacks; Mark Lawden; Arul Sivaguru; Brent J Gaskin; Saaeha Rauz; Carl E Clarke; Alexandra K Ball Journal: J Neurol Date: 2012-01-12 Impact factor: 4.849
Authors: Deborah I Friedman; Michael P McDermott; Karl Kieburtz; Mark Kupersmith; Ann Stoutenburg; John L Keltner; Steven E Feldon; Eleanor Schron; James J Corbett; Michael Wall Journal: J Neuroophthalmol Date: 2014-06 Impact factor: 3.042
Authors: Mark J Kupersmith; Patrick A Sibony; Steven E Feldon; Jui-Kai Wang; Mona Garvin; Randy Kardon Journal: Am J Ophthalmol Date: 2016-12-28 Impact factor: 5.258
Authors: Philipp Albrecht; Christine Blasberg; Marius Ringelstein; Ann-Kristin Müller; David Finis; Rainer Guthoff; Ella-Maria Kadas; Wolf Lagreze; Orhan Aktas; Hans-Peter Hartung; Friedemann Paul; Alexander U Brandt; Axel Methner Journal: J Neurol Date: 2017-06-05 Impact factor: 4.849
Authors: Catherine R Sheils; William S Fischer; Rachel A Hollar; Lisa M Blanchard; Steven E Feldon Journal: Am J Ophthalmol Date: 2018-08-04 Impact factor: 5.258
Authors: Imran Jivraj; Cesar A Cruz; Maxwell Pistilli; Anita A Kohli; Grant T Liu; Kenneth S Shindler; Robert A Avery; Mona K Garvin; Jui-Kai Wang; Ahmara Ross; Madhura A Tamhankar Journal: J Neuroophthalmol Date: 2021-12-01 Impact factor: 4.415